On August 19, 2026, the US Food and Drug Administration authorized the Aletta, the first standalone robotic device that draws blood from a patient's arm without hands-on operator intervention, granting Vitestro marketing authorization through the De Novo pathway for low- to moderate-risk devices of a new type. Alongside the authorization, the FDA established special controls that define mandatory requirements for labeling, performance testing, and clinical testing, which manufacturers of automated phlebotomy devices must meet to bring a comparable device to the US market. The FDA announced the action in a press release dated August 19, 2026.
The device is authorized for adults in outpatient settings and must operate under the oversight of a supervisor trained in phlebotomy, with one phlebotomist able to oversee up to three Aletta units at the same time. FDA positioned the authorization as a response to a growing US shortage of trained phlebotomists, noting that blood draws remain one of the most commonly performed medical procedures in the United States.
What did the FDA authorize, and through which pathway?
The Aletta received a De Novo classification order, the FDA route for novel low- to moderate-risk devices that have no prior predicate and therefore cannot go through the 510(k) substantial-equivalence path. A De Novo grant does two things at once: it authorizes the specific device for marketing, and it creates a new regulatory classification into which future devices of the same type will fall. For robotic blood draw systems this is the first such classification, so the special controls published with it set the template every follower device will be measured against.
The authorization covers a defined use: adults, outpatient settings, and supervised operation. It is not a clearance for pediatric use, inpatient acute-care deployment, or fully unattended operation, and manufacturers planning adjacent indications will need their own authorization.
Who must comply with the new special controls?
The special controls bind any manufacturer seeking to market a robotic or autonomous phlebotomy device in the United States under the new classification. They spell out requirements in three areas the FDA named explicitly: labeling, performance testing, and clinical testing. When a manufacturer meets the special controls together with the general controls of the FD&C Act, the combination provides the reasonable assurance of safety and effectiveness the agency requires for marketing.
For operations leads at outpatient lab networks and health systems evaluating the Aletta itself, the controls also define what the device must deliver: clinical performance comparable to or better than trained human phlebotomists when it proceeds with a stick, demonstrated across patients with varying health statuses, difficult vein access, and varying skin tones, with device-related adverse events remaining uncommon and mild.
How does the Aletta work, and what safety duties apply?
The device autonomously runs the full blood draw sequence after a trained phlebotomist initiates the session and remains available throughout. It uses near-infrared light and Doppler ultrasound to locate a suitable vein and tell it apart from arteries, and it will not attempt the procedure if no appropriate vein is found. Once a vein is identified, the Aletta applies a tourniquet, prepares the skin, inserts and disposes of the needle, changes collection tubes, and places a bandage on its own.
Safety layers are built into the authorization's expectations. The device continuously applies disinfectant to the skin during the ultrasound scan, a trained professional cleans it between patients, and if the patient moves too much the needle automatically detaches and the draw stops, while onboard sensors can pause the procedure and alert the supervisor. The supervising phlebotomist must confirm that collection tubes are filled in the correct order and are adequately full after the procedure. These duties sit alongside the existing 21 CFR Part 820 quality management system requirements, the QMSR that took effect on February 2, 2026, which already apply to device manufacturers.
| Parameter | What the De Novo authorization establishes |
|---|---|
| Authorized device | Vitestro Aletta, the first standalone robotic blood draw device |
| Pathway | De Novo classification (low- to moderate-risk, novel type with no predicate) |
| Use scope | Adults, outpatient settings, supervised operation only |
| Staffing model | One trained phlebotomist oversees up to three devices at once |
| Special controls | Labeling, performance testing, and clinical testing requirements |
| Safety triggers | Automatic needle-detach on patient movement; sensor-driven pause and supervisor alert |
| Quality system | 21 CFR Part 820 / QMSR applies to the manufacturer |
Continuous, per-jurisdiction monitoring of the kind Obsidian runs surfaces an FDA authorization like this the moment it publishes, before the special controls ripple through a manufacturer's compliance roadmap.
Take advantage of this real-time watch
Three steps for compliance and operations leads now. First, confirm whether your device or pipeline falls under the new robotic blood draw classification, which determines whether the Aletta's special controls are your direct baseline. Second, map your labeling, performance testing, and clinical testing programs against the three control areas the FDA named, and identify gaps before you invest in a De Novo submission. Third, brief your clinical and lab operations teams on the supervision model, the one-to-three staffing ratio, and the between-patient cleaning duties if you are evaluating the Aletta for deployment. Obsidian will track this new classification and any future special-control amendments as the FDA publishes them.
